Unichem gets USFDA nod for hypertension treatment tablets
NEW DELHI: Drug firm Unichem Laboratories has received approval from the US health regulator for its Losartan Potassium tablets used in treatment of hypertension."The company has received ANDA approval from the United States Food and Drug Administration (US FDA) for Losartan Potassium tablets USP," Unichem Laboratories said in a filing to BSE.The product will be commercialised from the...
Login or Register to read the full article
NEW DELHI: Drug firm Unichem Laboratories has received approval from the US health regulator for its Losartan Potassium tablets used in treatment of hypertension.
"The company has received ANDA approval from the United States Food and Drug Administration (US FDA) for Losartan Potassium tablets USP," Unichem Laboratories said in a filing to BSE.
The product will be commercialised from the company's Ghaziabad plant, it added.
The product is generic version of Merck Sharp & Dohme Corp's Cozaar tablets in the strength of 25 mg, 50 mg and 100 mg, Unichem said.
Losartan Potassium is used for treatment of hypertension, it added.
"The company has received ANDA approval from the United States Food and Drug Administration (US FDA) for Losartan Potassium tablets USP," Unichem Laboratories said in a filing to BSE.
The product will be commercialised from the company's Ghaziabad plant, it added.
The product is generic version of Merck Sharp & Dohme Corp's Cozaar tablets in the strength of 25 mg, 50 mg and 100 mg, Unichem said.
Losartan Potassium is used for treatment of hypertension, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd